Abrocitinib Responses Maintained Through Week 72 in JADE REAL
Key Takeaways
- JADE REAL evaluated flexible, investigator-directed abrocitinib dosing in 312 adolescents and adults with moderate-to-severe atopic dermatitis (AD).
- Treatment-emergent adverse events (TEAEs) occurred in 78.2% of patients; 36.9% had at least 1 dose change, according to the researchers.
- Among patients observed through Week 72, improvements in clinician- and patient-reported measures were seen from Week 4 and continued or were maintained through Week 72.
New research suggests that flexible abrocitinib dosing under conditions designed to simulate clinical practice was associated with improvements through Week 72 among observed patients with moderate-to-severe atopic dermatitis (AD).
Researchers for the JADE REAL trial enrolled 312 patients aged 12 years or older with moderate-to-severe AD and inadequate therapeutic options, and were assigned investigator-selected once-daily abrocitinib at 100 mg for 120 patients (38.5%) and 200 mg for 192 (61.5%), with subsequent dose adjustments permitted according to clinical response and safety.
Flexible Abrocitinib Dosing in JADE REAL
Overall, 115 patients (36.9%) had at least 1 dose change. Treatment-related adverse events (TEAEs) were reported in 78.2% of patients, and 17 patients (5.4%) experienced serious TEAEs. TEAEs led to dose reductions in 27 patients (8.7%) and dose escalation in 12 (3.8%). Two deaths occurred during the study; investigators considered 1 unrelated to treatment, while a relationship to study drug could not be ruled out for the other.
The investigators reported early improvement. At Week 4, EASI-75 was achieved by 36.1% of patients who initiated 100 mg and 57.8% who initiated 200 mg. Among patients with available Week 72 data, corresponding rates were 85.7% and 81.9%. EASI-90 rates increased from 18.5% and 31.6%, respectively, at Week 4 to 65.7% and 63.9% at Week 72. Improvements in itch and patient-reported AD severity were also observed from Week 4 through Week 72.
Interpretation is limited by the open-label, uncontrolled design, investigator-selected dosing, attrition, and declining patient numbers over time. Only 107 of the 312 enrolled patients were included in the Week 72 analysis.
“Most patients continued their initial dose of abrocitinib,” the authors concluded. “TEAEs accounted for a minority of documented dose reductions; instead, investigators may have determined that the patients’ disease could be maintained at a lower dose. These findings support clinical decision-making around dose selection and modification.”
Source
Chovatiya, R et al. Journal of Dermatological Treatment. 2026;37(1). Doi:10.1080/09546634.2026.2712186